U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07903857) titled 'SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors' on Oct. 18.
Brief Summary: This is a phase 1, multicenter, open-label, single-arm study evaluating SND002 Cell Injection in participants with advanced malignant solid tumors that have progressed after standard treatment or for whom no standard treatment is available.
SND002 Cell Injection is an investigational product made from a participant's own immune cells (T cells). These cells are collected from a lymph node that drains the tumor, expanded in a laboratory, and then given back to the same participant by intravenous infusion. Because the cells come from...